加载中
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
前收盘价
US$4.14
−US$0.35 · -7.80%
盘后
US$4.14
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
日内区间
当前US$4.14
52周区间
当前US$4.14
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
53
合理估值
情绪
69
看涨
风险
48
风险偏高
动量
61
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
日内区间
当前US$4.14
52周区间
当前US$4.14
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 977.3万 USD | 833.3万 USD | 1545.1万 USD | 250.2万 USD | — |
| 销货成本 | — | — | — | 248.7万 USD | — |
| 毛利 | 977.3万 USD | 833.3万 USD | 1545.1万 USD | 1.5万 USD | — |
| 研究与开发 | 8640.3万 USD | 6600.1万 USD | 5677.8万 USD | 9116.9万 USD | 1.32亿 USD |
| 销售、一般及管理费用 | 3386.8万 USD | 2895.3万 USD | 3004.7万 USD | 3487.3万 USD | 4132.4万 USD |
| 营业费用 | 1.2亿 USD | 9979.2万 USD | 8789万 USD | 1.26亿 USD | 1.73亿 USD |
| 利息收入 | 922.4万 USD | 694万 USD | 357.2万 USD | 24.9万 USD | 17.2万 USD |
| 利息支出 | 6.3万 USD | 10.2万 USD | 499.8万 USD | 379.8万 USD | 142.8万 USD |
| 折旧和摊销 | 114.5万 USD | 124.5万 USD | 137.1万 USD | 117.2万 USD | 49.2万 USD |
| 营业利润 | −1.1亿 USD | −9145.9万 USD | −7243.9万 USD | −1.26亿 USD | −1.73亿 USD |
| 净利润 | −1.09亿 USD | −8929.8万 USD | −1.12亿 USD | −1.66亿 USD | −1.75亿 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
